DBV Technologies (NASDAQ:DBVT) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research note issued on Friday. The brokerage set a “hold” rating on the stock.

A number of other equities research analysts have also issued reports on DBVT. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 target price on shares of DBV Technologies in a research note on Thursday, August 1st. JMP Securities restated a “market outperform” rating and issued a $5.00 price objective on shares of DBV Technologies in a research report on Tuesday, September 24th.

DBV Technologies Stock Performance

DBV Technologies stock opened at $0.70 on Friday. The firm has a market capitalization of $67.15 million, a price-to-earnings ratio of -0.83 and a beta of 0.68. DBV Technologies has a fifty-two week low of $0.50 and a fifty-two week high of $2.74. The stock’s fifty day moving average is $0.86 and its two-hundred day moving average is $1.07.

DBV Technologies (NASDAQ:DBVT) last posted its earnings results on Tuesday, July 30th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.08). DBV Technologies had a negative net margin of 638.21% and a negative return on equity of 74.41%. The business had revenue of $1.16 million for the quarter, compared to analysts’ expectations of $1.42 million. During the same quarter last year, the business posted ($0.26) earnings per share. As a group, sell-side analysts forecast that DBV Technologies will post -1.43 EPS for the current fiscal year.

Institutional Trading of DBV Technologies

A hedge fund recently raised its stake in DBV Technologies stock. Yiheng Capital Management L.P. lifted its stake in shares of DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,568,909 shares of the company’s stock after acquiring an additional 327,345 shares during the period. DBV Technologies accounts for about 0.2% of Yiheng Capital Management L.P.’s investment portfolio, making the stock its 15th largest position. Yiheng Capital Management L.P. owned 2.89% of DBV Technologies worth $4,172,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 71.74% of the stock is owned by hedge funds and other institutional investors.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.